Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2019, with a specific transaction date of October 30, 2019. The document serves as a transaction notification regarding the acquisition of notional shares by Persons Discharging Managerial Responsibilities (PDMRs), specifically Non-Executive Directors, under the company's share allocation arrangements for the service period of July 1, 2019, to September 30, 2019.
Key Financial Metrics
This filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific equity transactions.
| Director Name | Position | Instrument | Volume | Price |
|---|---|---|---|---|
| Mr Jonathan Symonds | Non-Executive Chairman | Ordinary Shares | 833.830 | £17.25 |
| Mr Vindi Banga | Senior Independent Non-Executive Director | Ordinary Shares | 416.667 | £17.25 |
| Dr Vivienne Cox | Independent Non-Executive Director | Ordinary Shares | 307.971 | £17.25 |
| Ms Lynn Elsenhans | Independent Non-Executive Director | ADSs | 1,117.592 | $44.27 |
| Dr Laurie Glimcher | Independent Non-Executive Director | ADSs | 1,241.769 | $44.27 |
| Dr Jesse Goodman | Independent Non-Executive Director | ADSs | 374.672 | $44.27 |
| Ms Judy Lewent | Independent Non-Executive Director | ADSs | 417.491 | $44.27 |
| Mr Urs Rohner | Independent Non-Executive Director | Ordinary Shares | 416.667 | £17.25 |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely documents the routine allocation of notional shares to Non-Executive Directors as compensation for the third quarter of 2019.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on business performance, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share transactions.
Investor Verification Points
- Verify the total number of Ordinary Shares and ADSs allocated to Non-Executive Directors for the Q3 2019 period.
- Confirm the transaction price of £17.25 per Ordinary Share and $44.27 per ADS against market prices on October 30, 2019.
- Note that these are "notional" acquisitions under share allocation arrangements, not open market purchases by the directors.
- Review the company's annual Form 20-F for comprehensive financial data, as this Form 6-K contains no financial statements.